ICAM-1-based rabies virus vaccine shows increased infection and activation of primary murine B cells In Vitro and enhanced antibody titers In-Vivo

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Norton Jr , James E ^a   Lytle, Andrew G ^a   Shen, Shixue ^a   Tzvetkov, Evgeni P ^a   Dorfmeier, Corin L ^a   McGettigan, James P ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD69 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RABIES VACCINE;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; FEMALE; GENE PRODUCT; GENOME; HAMSTER; ICAM1 GENE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; RABIES; REVERSE GENETICS; UPREGULATION; VIRUS GENE; VIRUS PARTICLE;

ANIMALS; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CELL LINE; CRICETINAE; FEMALE; GENE EXPRESSION; GENOME, VIRAL; HUMANS; IMMUNITY, HUMORAL; INTERCELLULAR ADHESION MOLECULE-1; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MICE; MICE, INBRED C57BL; RABIES; RABIES VACCINES; RABIES VIRUS; RECOMBINANT FUSION PROTEINS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL PROTEINS; VIRION;

EID: 84900313652     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087098     Document Type: Article

References (45)

1. CDC website. Available: http://www.cdc.gov/rabies/location/usa/cost.html. Accessed 2014 Jan 6.
2. WHO (2013) WHO rabies fact sheet, no.99.
3. Lackay SN, Kuang Y, Fu ZF (2008) Rabies in small animals. Vet Clin North Am Small Anim Pract 38: 851-61,, ix. 10.1016/j.cvsm.2008.03.003; 10.1016/j.cvsm.2008.03.003.
4. Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, et al. (2010) Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: Recommendations of the advisory committee on immunization practices. MMWR Recomm Rep 59: 1-9.
5. McGettigan JP (2010) Experimental rabies vaccines for humans. Expert Rev Vaccines 9: 1177-1186. 10.1586/erv.10.105; 10.1586/erv.10.105.
6. Ertl HC (2009) Novel vaccines to human rabies. PLoS Negl Trop Dis 3: e515.
7. Strady C, Andreoletti L, Baumard S, Servettaz A, Jaussaud R, et al. (2009) Immunogenicity and booster efficacy of pre-exposure rabies vaccination. Trans R Soc Trop Med Hyg 103: 1159-1164. 10.1016/j.trstmh.2009.03.007.
8. Cenna J, Hunter M, Tan GS, Papaneri AB, Ribka EP, et al. (2009) Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. Journal of Infectious Diseases 200: 1251-60.
9. Dorfmeier CL, Lytle AG, Dunkel AL, Gatt A, McGettigan JP (2012) Protective vaccine-induced CD4(+) T cell-independent B cell responses against rabies infection. J Virol 86: 11533-11540. 10.1128/JVI.00615-12; 10.1128/JVI.00615-12.
10. Dorfmeier CL, Shen S, Tzvetkov EP, McGettigan JP (2013) Reinvestigating the role of IgM in rabies virus post-exposure vaccination. J Virol. 10.1128/JVI.00995-13.
11. Lytle AG, Norton EJ, Dorfmeier CL, Shen S, McGettigan JP (2013) B cell infection and activation by rabies virus-based vaccines. In Press.
12. Staunton DE, Marlin SD, Stratowa C, Dustin ML, Springer TA (1988) Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell 52: 925-933.
13. Sanchez-Madrid F, Nagy JA, Robbins E, Simon P, Springer TA (1983) A human leukocyte differentiation antigen family with distinct alpha-subunits and a common beta-subunit: The lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/mac-1), and the p150,95 molecule. J Exp Med 158: 1785-1803. (Pubitemid 14210788)
14. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA (1986) Induction by IL 1 and interferon-gamma: Tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 137: 245-254. (Pubitemid 16100296)
15. Kurzinger K, Reynolds T, Germain RN, Davignon D, Martz E, et al. (1981) A novel lymphocyte function-associated antigen (LFA-1): Cellular distribution, quantitative expression, and structure. J Immunol 127: 596-602. (Pubitemid 11054672)
16. Gaglia JL, Greenfield EA, Mattoo A, Sharpe AH, Freeman GJ, et al. (2000) Intercellular adhesion molecule 1 is critical for activation of CD28-deficient T cells. J Immunol 165: 6091-6098.
17. Shinde S, Wu Y, Guo Y, Niu Q, Xu J, et al. (1996) CD40L is important for induction of, but not response to, costimulatory activity. ICAM-1 as the second costimulatory molecule rapidly up-regulated by CD40L. J Immunol 157: 2764-2768. (Pubitemid 126450028)
18. Dubey C, Croft M, Swain SL (1995) Costimulatory requirements of naive CD4+ T cells. ICAM-1 or B7-1 can costimulate naive CD4 T cell activation but both are required for optimum response. J Immunol 155: 45-57.
19. Cantin R, Methot S, Tremblay MJ (2005) Plunder and stowaways: Incorporation of cellular proteins by enveloped viruses. J Virol 79: 6577-6587. 10.1128/JVI.79.11.6577-6587.2005. (Pubitemid 40677289)
20. Tardif MR, Tremblay MJ (2003) Presence of host ICAM-1 in human immunodeficiency virus type 1 virions increases productive infection of CD4+ T lymphocytes by favoring cytosolic delivery of viral material. J Virol 77: 12299-12309. (Pubitemid 37339882)
21. Kondo N, Melikyan GB (2012) Intercellular adhesion molecule 1 promotes HIV-1 attachment but not fusion to target cells. PLoS One 7: e44827. 10.1371/journal.pone.0044827; 10.1371/journal.pone.0044827.
22. Fortin JF, Cantin R, Lamontagne G, Tremblay M (1997) Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol 71: 3588-3596. (Pubitemid 27172369)
23. Carrasco YR, Fleire SJ, Cameron T, Dustin ML, Batista FD (2004) LFA-1/ICAM-1 interaction lowers the threshold of B cell activation by facilitating B cell adhesion and synapse formation. Immunity 20: 589-599. (Pubitemid 38638128)
24. Dennig D, Lacerda J, Yan Y, Gasparetto C, O'Reilly RJ (1994) ICAM-1 (CD54) expression on B lymphocytes is associated with their costimulatory function and can be increased by coactivation with IL-1 and IL-7. Cell Immunol 156: 414-423. 10.1006/cimm.1994.1186.
25. Schnell MJ, Foley HD, Siler CA, McGettigan JP, Dietzschold B, et al. (2000) Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci U S A 97: 3544-9. (Pubitemid 30183339)
26. Conzelmann KK, Cox JH, Schneider LG, Thiel HJ (1990) Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19. Virology 175: 485-99. (Pubitemid 20133450)
27. McGettigan JP, Pomerantz RJ, Siler CA, McKenna PM, Foley HD, et al. (2003) Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. Journal of Virology. 77: 237-44. (Pubitemid 36004964)
28. McGettigan JP, Naper K, Orenstein J, Koser M, McKenna PM, et al. (2003) Functional human immunodeficiency virus type 1 (HIV-1) gag-pol or HIV-1 gag-pol and env expressed from a single rhabdovirus-based vaccine vector genome. Journal of Virology. 77: 10889-99. (Pubitemid 37204282)
29. Dorfmeier CL, Tzvetkov EP, Gatt A, McGettigan JP (2013) Investigating the role for IL-21 in rabies virus vaccine-induced immunity. PLoS Negl Trop Dis 7: e2129. 10.1371/journal.pntd.0002129; 10.1371/journal.pntd.0002129.
30. Dorfmeier CL, Lytle AG, Dunkel AL, Gatt A, McGettigan JP (2012) Protective vaccine-induced CD4+ T cell-independent B cell responses against rabies infection. J Virol. 10.1128/JVI.00615-12.
31. Dorfmeier CL, Tzvetkov EP, Gatt A, McGettigan JP (2013) Investigating the role for IL-21 in rabies virus vaccine-induced immunity. PLoS Negl Trop Dis 3: e2129.
32. Cenna J, Tan GS, Papaneri AB, Dietzschold B, Schnell MJ, et al. (2008) Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene. Vaccine 26: 6405-14.
33. Mebatsion T, Conzelmann KK (1996) Specific infection of CD4+ target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike protein. Proc Natl Acad Sci U S A 93: 11366-11370. (Pubitemid 26347127)
34. Siler CA, McGettigan JP, Dietzschold B, Herrine SK, Dubuisson J, et al. (2002) Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology 292: 24-34. (Pubitemid 34925835)
35. Moore SM, Hanlon CA (2010) Rabies-specific antibodies: Measuring surrogates of protection against a fatal disease. PLoS Negl Trop Dis 4: e595. 10.1371/journal.pntd.0000595; 10.1371/journal.pntd.0000595.
36. Plotkin SA (2008) Vaccines: Correlates of vaccine-induced immunity. Clin Infect Dis 47: 401-409. 10.1086/589862.
37. WHO. (1997) WHO recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies.
38. Bromley SK, Iaboni A, Davis SJ, Whitty A, Green JM, et al. (2001) The immunological synapse and CD28-CD80 interactions. Nat Immunol 2: 1159-1166. 10.1038/ni737. (Pubitemid 33130151)
39. Mebatsion T, Finke S, Weiland F, Conzelmann KK (1997) A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell 90: 841-847. (Pubitemid 27381623)
40. Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, et al. (2011) Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and ebola viruses. J Virol 85: 10605-10616. 10.1128/JVI.00558-11; 10.1128/JVI.00558-11.
41. Testi R, D'Ambrosio D, De Maria R, Santoni A (1994) The CD69 receptor: A multipurpose cell-surface trigger for hematopoietic cells. Immunol Today 15: 479-483. 10.1016/0167-5699(94)90193-7. (Pubitemid 24316014)
42. Ziegler SF, Ramsdell F, Alderson MR (1994) The activation antigen CD69. Stem Cells 12: 456-465. 10.1002/stem.5530120502. (Pubitemid 24278225)
43. Grewal IS, Flavell RA (1998) CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16: 111-135. 10.1146/annurev.immunol.16.1.111. (Pubitemid 28183361)
44. Grewal IS, Foellmer HG, Grewal KD, Xu J, Hardardottir F, et al. (1996) Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 273: 1864-1867. (Pubitemid 26322497)
45. Neefjes J, Jongsma ML, Paul P, Bakke O (2011) Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 11: 823-836. 10.1038/nri3084; 10.1038/nri3084.